FHND 5071
Alternative Names: FHND-5071Latest Information Update: 28 Apr 2023
At a glance
- Originator Jiangsu Chia Tai Fenghai Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 26 Apr 2023 Jiangsu Chia Tai Fenghai Pharmaceuticals plans a phase I trial for Solid tumor in USA
- 07 Jul 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT05818917)
- 27 May 2022 US FDA approves IND application for FHND 5071 in Solid tumors